Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | CBLB | Q13191 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11994324 | 0.72 | IDH1 (0.39) | IDH1IDH2 | |
| SCHEMBL25998075 | 0.70 | IDH1 (0.30) | IDH1IDH2 | |
| SCHEMBL19706482 | 0.67 | MDM2 (0.37) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL24985772 | 0.67 | RXRA (0.34) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL20889866 | 0.67 | LMNA (0.37) | CBLBIDH1IDH2 | |
| SCHEMBL20890457 | 0.66 | IDH1 (0.38) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL26791964 | 0.64 | LOXL2 (0.35) | CYP3A4CYP2D6CBLB | |
| SCHEMBL25707474 | 0.63 | LMNA (0.36) | CBLB | |
| SCHEMBL25636065 | 0.63 | IDH1 (0.38) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL31691837 | 0.63 | IDH1 (0.38) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP3A4 4349/4885CYP2D6 4304/4885TSHR 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.